A new study from a Massachusetts General Hospital (MGH) research team has found that the hypertension drug losartan, which targets the angiotensin signaling pathway, may improve the effectiveness of chemotherapy agents used to treat ovarian cancer. Previous research from the … Read more
A randomized phase 3 trial designed to evaluate avelumab for women with previously untreated advanced ovarian cancer failed to achieve its primary endpoint of PFS.
The JAVELIN Ovarian 100 study has been terminated based on the finding, reported as part … Read more
By Brielle Benyon
The Food and Drug Administration (FDA) approved Lynparza (olaparib) for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a… Read more
Many Americans hold the misguided view that alternative therapies alone can cure cancer, even though such methods are not proven to be effective in treating cancer, according to a new survey.
The survey, known as the National … Read more
Cancer patients could be spared unnecessary chemotherapy – and its side effects – by a new blood test that is in clinical trials at more than 40 hospitals in Australia and New Zealand.
The trials, led by Melbourne researchers, are … Read more
Ovarian tumors disable the immune system’s killer T cells—which protect the body by destroying infected or malignant cells—enabling the disease to flourish unchecked, according to a new study by Weill Cornell Medicine scientists. The findings show that adverse conditions within … Read more
The extent to which the BRCA1 promoter is methylated could signal an ovarian tumor’s susceptibility to PARP inhibitor treatment, a new study has found.
PARP inhibitor treatment has been effective in treating some patients with high-grade serous ovarian carcinoma with … Read more
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but never to a cure. About 15 percent of… Read more
An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival … Read more
Combining a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.
The combination of targeted drug vistusertib along with paclitaxel chemotherapy … Read more
Proponents of precision medicine cite the growing numbers of successful precision cancer drugs. The examples of Herceptin (trastuzumab), Gleevec (imatinib mesylate), Xalkori (crizotinib), and Zelboraf (vemurafenib) come to mind. Skeptics, on the other hand, focus on the … Read more
by Madeline Marr
The use of niraparib in women receiving treatment for platinum-sensitive recurrent ovarian cancer did not adversely affect quality of life (QoL), according to a study published in The Lancet Oncology.
An international team of researchers led … Read more